Adcirca(TM) (tadalafil) is now available in Canada for the treatment of pulmonary arterial hypertension (PAH). Adcirca represents an important new and convenient option for the estimated 2,000 to 10,000 Canadians with this rare but progressive and serious disorder. Characterized by an elevation of pressure in the pulmonary (lung) arteries, PAH can lead to shortness of breath, fatigue, heart failure and often leads to death within four years of diagnosis.(1)
